Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR -positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials.
Wu-Sheng DengKe WangYun JiangDingbin LiChongxi BaoJing LuoLiuyuan LiuBing HuangJinliang KongPublished in: BMJ open (2022)
advanced NSCLC was associated with significantly prolonged PFS compared with erlotinib alone, but the combination did not prolong OS.